LY243246
Code | Size | Price |
---|
TAR-T27933-5mg | 5mg | £1,492.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27933-50mg | 50mg | £2,946.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T27933-100mg | 100mg | £4,006.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
LY249543, the S-isomer of lometrexol, is an inhibitor of Methylenetetrahydrofolate Dehydrogenase/Cycl.
CAS:
106400-18-4
Formula:
C21H23N5Na2O6
Molecular Weight:
487.424
Purity:
0.98
SMILES:
[Na+].[Na+].Nc1nc(=O)c2CC(CCc3ccc(cc3)C(=O)NC(CCC([O-])=O)C([O-])=O)CNc2[nH]1
References
1. Roberts JD, Poplin EA, Tombes MB, Kyle B, Spicer DV, Grant S, Synold T, Moran R. Weekly lometrexol with daily oral folic acid is appropriate for phase II evaluation. Cancer Chemother Pharmacol. 2000;45(2):103-10. PubMed PMID: 10663624.
2. Synold TW, Newman EM, Carroll M, Muggia FM, Groshen S, Johnson K, Doroshow JH. Cellular but not plasma pharmacokinetics of lometrexol correlate with the occurrence of cumulative hematological toxicity. Clin Cancer Res. 1998 Oct;4(10):2349-55. PubMed PMID: 9796964.
3. Habeck LL, Chay SH, Pohland RC, Worzalla JF, Shih C, Mendelsohn LG. Whole-body disposition and polyglutamate distribution of the GAR formyltransferase inhibitors LY309887 and lometrexol in mice: effect of low-folate diet. Cancer Chemother Pharmacol. 1998;41(3):201-9. PubMed PMID: 9443636.
4. Turner RN, Aherne GW, Curtin NJ. Selective potentiation of lometrexol growth inhibition by dipyridamole through cell-specific inhibition of hypoxanthine salvage. Br J Cancer. 1997;76(10):1300-7. PubMed PMID: 9374375; PubMed Central PMCID: PMC2228144.